Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

被引：11

作者：

Gonzalez, Humberto C. ^{[1
]}

Jafri, Syed-Mohammed ^{[2
]}

Gordon, Stuart C. ^{[2
]}

机构：

[1] Univ Tennessee, Hlth Sci Ctr, Methodist Univ Hosp, Dept Transplant Surg,Ctr Adv Liver Dis, 1211 Union Ave,Suite 340, Memphis, TN 38104 USA

[2] Henry Ford Hlth Syst, Div Gastroenterol & Hepatol, 2799 West Grand Blvd, Detroit, MI 48202 USA

来源：

CLINICS IN LIVER DISEASE | 2017年 / 21卷 / 01期

关键词：

Drug-induced liver injury; Acute liver failure; Liver support systems; Artificial liver support systems; Bioartificial liver support systems; FULMINANT HEPATIC-FAILURE; ADSORBENT RECIRCULATING SYSTEM; RESERVOIR BIOARTIFICIAL LIVER; INTRAVENOUS N-ACETYLCYSTEINE; CAUSALITY ASSESSMENT METHODS; RANDOMIZED CONTROLLED-TRIAL; HIGH-VOLUME PLASMAPHERESIS; TYLENOL EXTENDED RELIEF; ACETAMINOPHEN OVERDOSE; ACTIVATED-CHARCOAL;

D O I：

10.1016/j.cld.2016.08.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Drug-induced liver injury (DILI) can be predictable or idiosyncratic and has an estimated incidence of approximately 20 cases per 100,000 persons per year. DILI is a common cause of acute liver failure in the United States. No accurate tests for diagnosing DILI exist, and its diagnosis is based on exclusion of other conditions. Managing DILI includes discontinuing the suspected causative agent and in selected cases administering an antidote. Liver support systems are used for long-term support or as a bridge to transplantation and are effective for improving encephalopathy, hyper-bilirubinemia, and other liver-related conditions, but whether they improve survival remains uncertain.

引用

页码：163 / +

页数：19

共 101 条

[1]

Akin A, 2013, J DRUG METAB TOXICOL, V4, P160

[2] LIVER TOXICITY AFTER ACETAMINOPHEN INGESTION INADEQUACY OF DOSE ESTIMATE AS AN INDEX OF RISK [J].